N/A N=62 PHIL in the Treatment of Intracranial dAVF.
Arteriovenous Dural Fistula
Primary: Subjects With Neurological Death or Ipsilateral Stroke — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=14 Treating Arteriovenous Malformation With Stereotactic Radiosurgery Using CT Angiography for Treatment Planning
Arteriovenous Malformations
Primary: Target Volume Difference Between Standard of Care vs. CT Angiogram and MRI Alone — 1.1; 1.3 mL
N/A N=164 Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
N/A N=18 Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations
Intracranial Arteriovenous Malformations (AVM)
Primary: Number of Participants With Presence of T2 Weighted Changes on Serial MRI Exam Associated With New Neurological Symptoms — 2 participants
N/A N=92 A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes. To Evaluate the Safety and Effectiveness of ArtiFascia® in Subjects Requiring Dural Repair.
Dural Tear · Cerebrospinal Fluid Leak
Primary: Absence of Cerebrospinal Fluid Fistula (Drainage From Wound or Sinus) and Pseudo-meningocele Within 6 Months Post-operative as Evaluated by MRI Imaging. — 0; 0; 27; 58…
N/A N=144 VasQ External Support for Arteriovenous Fistula
Arterio-Venous Fistula · ESRD · Steal Syndrome
Primary: Primary Patency of AVF — 88 Participants
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
N/A N=16 Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Subclavian Steal
Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants
Phase 2 N=75 Fibrin Sealant for the Sealing of Dura Sutures
Pathological Processes in the Posterior Fossa · Dura Defects
Primary: Incidence of Cerebrospinal Fluid (CSF) Leakage Observed After Surgery — 74.07; 78.13 percentage of participants — p=0.7159
N/A N=103 Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants
N/A N=20 Internal Jugular Vein Compression Collar for Novel Symptomatic Treatment of Venous Pulsatile Tinnitus
Pulsatile Tinnitus
Primary: Change From Baseline in Pulsatile Tinnitus Symptom Intensity — 3 units on a scale — p=<0.0001
N/A N=12 Internal Jugular Vein Flow in the Sitting Position
Jugular Venous Flow
Primary: Internal Jugular Venous Flow — 0.04; 0.4; 0.04; 0.21 cm2
N/A N=138 Reverse Medical Barrel™ Device for Adjunctive Treatment for Wide-Neck, Intracranial, Bifurcating/Branching Aneurysms
Intracranial Bifurcating Aneurysms
Primary: Number of Participants With Neurologic Death or Major Ipsilateral Stroke Within 12 Month Follow-up Period. — 5 Participants
Phase 3 N=224 Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery
Cerebrospinal Fluid Leak
Primary: Number of Participants With No CSF Leak During and After Surgery — 76; 87 Participants
Phase 2 N=13 Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access
AV Fistula
Primary: Time to AV Fistula Functional Maturation — 169; 145 Days to functional maturation
N/A N=121 Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study
Arteriovenous Malformations
Primary: Number of Participants With Catheter-related Adverse Events at 30 Days — 0 Participants
N/A N=376 Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
Chronic Subdural Hematoma
Primary: Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any…
N/A N=227 Pivotal Study for the FLAIR Endovascular Stent Graft
Stenoses
Primary: Percent of Participants With Treatment Area Primary Patency (TAPP) — 51; 23; 60 Percentage of Participants — p=<0.001
N/A N=280 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
Stenosis · Restenosis
Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001
N/A N=330 IN.PACT™ AV Access IDE Study
Arteriovenous Fistula Stenosis · Arteriovenous Fistula Occlusion · Arteriovenous Fistula
Primary: Target Lesion Primary Patency Rate Through 6 Months — 125; 88 Participants — p=<0.001
N/A N=132 Study to Evaluate Cerebral AneurysmFlow Results in Occlusion
Intracranial Aneurysm
Primary: Prognostic Value of the MAFA (Mean Aneurysm Flow Amplitude) Ratio With Respect to Full Aneurysm Occlusion Within 12 Months — 0.540 probability
Phase 3 N=54 Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
End Stage Renal Disease · AV Fistula · Kidney Failure
Primary: Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis — 49 participants
N/A N=46 Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)
Kidney Diseases
Primary: Vein Diameter — 1.692; 2.100 millimeters — p=0.012
N/A N=31 Handgrip Exercise for Arteriovenous Fistula Maturation
Chronic Kidney Disease
Primary: Venous Diameter. — 5.78; 6.42 mm
N/A N=12 Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (AVess FIH)
Hemodialysis Access Failure
Primary: Number of Participants With Target Lesion Primary Patency at 6 Months Post Procedure — 11 Participants
Phase 3 N=285 Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae
Arteriovenous Fistula
Primary: Percentage of Participants With Target Lesion Primary Patency (TLPP) at 6 Months Post Index Procedure — 71.4; 63 Percentage of Participants — p=0.0562
N/A N=26 Catheter System Feasibility Clinical Trial
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
N/A N=110 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
Stenosis · Restenosis
Primary: Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events — 106 Participants — p=0.0021
Phase 2 N=12 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
Vestibular Schwannoma
Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants
N/A N=168 AMBULATE Continued Access Protocol to Evaluate the Cardiva Mid-Bore Venous Vascular Closure System (VVCS)
Surgical Wound
Primary: Number of Participants With Overall Procedure Success - Effectiveness — 168 Participants